Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18538879 | 0.88 | MAPT (0.50) | SIGMAR1MAPTPOLBHTTSMN1; SMN2 | |
| SCHEMBL29300046 | 0.88 | — | — | |
| SCHEMBL13184240 | 0.82 | TP53 (0.53) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12847850 | 0.82 | MAPT (0.60) | SIGMAR1MAPTPOLBHTTALDH1A1 | |
| SCHEMBL10153805 | 0.81 | PKM (0.57) | MAPTPOLBHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL12252064 | 0.81 | PKM (0.45) | MAPTPOLBHTTSMN1; SMN2PKM | |
| SCHEMBL13793792 | 0.81 | ALDH1A1 (0.53) | PIK3CDCYP1A2TDP1MAPTHTT | |
| SCHEMBL19928655 | 0.81 | SIGMAR1 (0.56) | SIGMAR1PIK3CDCYP1A2TDP1DRD3 | |
| SCHEMBL26448356 | 0.81 | SMN1; SMN2 (0.64) | SIGMAR1PIK3CDCYP1A2TDP1DRD3 | |
| SCHEMBL5109896 | 0.80 | MAPT (0.62) | CYP1A2MAPTPOLBHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2021189051-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160318878-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| WO-2015089479-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089481-A2 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SIGMAR1 4181/4885PIK3CD 354/4885CYP1A2 3850/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SIGMAR1 4097/4885PIK3CD 338/4885CYP1A2 3371/4885 |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SIGMAR1 4181/4885PIK3CD 354/4885CYP1A2 3850/4885 |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SIGMAR1 4097/4885PIK3CD 338/4885CYP1A2 3371/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SIGMAR1 4181/4885PIK3CD 354/4885CYP1A2 3850/4885 |
| US-20160318878-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SIGMAR1 4259/4885PIK3CD 372/4885CYP1A2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.